These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 23382571)

  • 101. Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study.
    Mocroft A; Lundgren JD; Ross M; Law M; Reiss P; Kirk O; Smith C; Wentworth D; Neuhaus J; Fux CA; Moranne O; Morlat P; Johnson MA; Ryom L; ; ; ; ;
    PLoS Med; 2015 Mar; 12(3):e1001809. PubMed ID: 25826420
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Predictors of advanced chronic kidney disease and end-stage renal disease in HIV-positive persons.
    Ryom L; Mocroft A; Kirk O; Ross M; Reiss P; Fux CA; Morlat P; Moranne O; Smith C; El-Sadr W; Law M; Lundgren JD
    AIDS; 2014 Jan; 28(2):187-99. PubMed ID: 24361680
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Protease Inhibitors and Renal Function in Patients with HIV Infection: a Systematic Review.
    Bagnis CI; Stellbrink HJ
    Infect Dis Ther; 2015 Jan; 4(1):15-50. PubMed ID: 25567681
    [TBL] [Abstract][Full Text] [Related]  

  • 104. HIV infection and the risk of acute myocardial infarction.
    Freiberg MS; Chang CC; Kuller LH; Skanderson M; Lowy E; Kraemer KL; Butt AA; Bidwell Goetz M; Leaf D; Oursler KA; Rimland D; Rodriguez Barradas M; Brown S; Gibert C; McGinnis K; Crothers K; Sico J; Crane H; Warner A; Gottlieb S; Gottdiener J; Tracy RP; Budoff M; Watson C; Armah KA; Doebler D; Bryant K; Justice AC
    JAMA Intern Med; 2013 Apr; 173(8):614-22. PubMed ID: 23459863
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration.
    Smith CJ; Ryom L; Weber R; Morlat P; Pradier C; Reiss P; Kowalska JD; de Wit S; Law M; el Sadr W; Kirk O; Friis-Moller N; Monforte Ad; Phillips AN; Sabin CA; Lundgren JD;
    Lancet; 2014 Jul; 384(9939):241-8. PubMed ID: 25042234
    [TBL] [Abstract][Full Text] [Related]  

  • 106. A chronic kidney disease risk score to determine tenofovir safety in a prospective cohort of HIV-positive male veterans.
    Scherzer R; Gandhi M; Estrella MM; Tien PC; Deeks SG; Grunfeld C; Peralta CA; Shlipak MG
    AIDS; 2014 Jun; 28(9):1289-95. PubMed ID: 24922479
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Hypophosphatemic osteomalacia induced by tenofovir in HIV-infected patients.
    Mateo L; Holgado S; Mariñoso ML; Pérez-Andrés R; Bonjoch A; Romeu J; Olivé A
    Clin Rheumatol; 2016 May; 35(5):1271-9. PubMed ID: 24794489
    [TBL] [Abstract][Full Text] [Related]  

  • 108. HIV and kidney diseases: 35 years of history and consequences.
    Campos P; Ortiz A; Soto K
    Clin Kidney J; 2016 Dec; 9(6):772-781. PubMed ID: 27994853
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.
    Sax PE; Wohl D; Yin MT; Post F; DeJesus E; Saag M; Pozniak A; Thompson M; Podzamczer D; Molina JM; Oka S; Koenig E; Trottier B; Andrade-Villanueva J; Crofoot G; Custodio JM; Plummer A; Zhong L; Cao H; Martin H; Callebaut C; Cheng AK; Fordyce MW; McCallister S;
    Lancet; 2015 Jun; 385(9987):2606-15. PubMed ID: 25890673
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 Results.
    Arribas JR; Thompson M; Sax PE; Haas B; McDonald C; Wohl DA; DeJesus E; Clarke AE; Guo S; Wang H; Callebaut C; Plummer A; Cheng A; Das M; McCallister S
    J Acquir Immune Defic Syndr; 2017 Jun; 75(2):211-218. PubMed ID: 28282300
    [TBL] [Abstract][Full Text] [Related]  

  • 111. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.
    ; Danel C; Moh R; Gabillard D; Badje A; Le Carrou J; Ouassa T; Ouattara E; Anzian A; Ntakpé JB; Minga A; Kouame GM; Bouhoussou F; Emieme A; Kouamé A; Inwoley A; Toni TD; Ahiboh H; Kabran M; Rabe C; Sidibé B; Nzunetu G; Konan R; Gnokoro J; Gouesse P; Messou E; Dohoun L; Kamagate S; Yao A; Amon S; Kouame AB; Koua A; Kouamé E; Ndri Y; Ba-Gomis O; Daligou M; Ackoundzé S; Hawerlander D; Ani A; Dembélé F; Koné F; Guéhi C; Kanga C; Koule S; Séri J; Oyebi M; Mbakop N; Makaila O; Babatunde C; Babatounde N; Bleoué G; Tchoutedjem M; Kouadio AC; Sena G; Yededji SY; Assi R; Bakayoko A; Mahassadi A; Attia A; Oussou A; Mobio M; Bamba D; Koman M; Horo A; Deschamps N; Chenal H; Sassan-Morokro M; Konate S; Aka K; Aoussi E; Journot V; Nchot C; Karcher S; Chaix ML; Rouzioux C; Sow PS; Perronne C; Girard PM; Menan H; Bissagnene E; Kadio A; Ettiegne-Traore V; Moh-Semdé C; Kouame A; Massumbuko JM; Chêne G; Dosso M; Domoua SK; N'Dri-Yoman T; Salamon R; Eholié SP; Anglaret X
    N Engl J Med; 2015 Aug; 373(9):808-22. PubMed ID: 26193126
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.
    ; Lundgren JD; Babiker AG; Gordin F; Emery S; Grund B; Sharma S; Avihingsanon A; Cooper DA; Fätkenheuer G; Llibre JM; Molina JM; Munderi P; Schechter M; Wood R; Klingman KL; Collins S; Lane HC; Phillips AN; Neaton JD
    N Engl J Med; 2015 Aug; 373(9):795-807. PubMed ID: 26192873
    [TBL] [Abstract][Full Text] [Related]  

  • 113. A clinically useful risk-score for chronic kidney disease in HIV infection.
    Mocroft A; Lundgren J; Ross M; Law M; Reiss P; Kirk O; Smith C; Wentworth D; Heuhaus J; Fux C; Moranne O; Morlat P; Johnson M; Ryom L;
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19514. PubMed ID: 25394023
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Long-term exposure to tenofovir continuously decrease renal function in HIV-1-infected patients with low body weight: results from 10 years of follow-up.
    Nishijima T; Kawasaki Y; Tanaka N; Mizushima D; Aoki T; Watanabe K; Kinai E; Honda H; Yazaki H; Tanuma J; Tsukada K; Teruya K; Kikuchi Y; Gatanaga H; Oka S
    AIDS; 2014 Aug; 28(13):1903-10. PubMed ID: 25259702
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.
    Raffi F; Jaeger H; Quiros-Roldan E; Albrecht H; Belonosova E; Gatell JM; Baril JG; Domingo P; Brennan C; Almond S; Min S;
    Lancet Infect Dis; 2013 Nov; 13(11):927-35. PubMed ID: 24074642
    [TBL] [Abstract][Full Text] [Related]  

  • 116. Effect of Cumulating Exposure to Abacavir on the Risk of Cardiovascular Disease Events in Patients From the Swiss HIV Cohort Study.
    Young J; Xiao Y; Moodie EE; Abrahamowicz M; Klein MB; Bernasconi E; Schmid P; Calmy A; Cavassini M; Cusini A; Weber R; Bucher HC;
    J Acquir Immune Defic Syndr; 2015 Aug; 69(4):413-21. PubMed ID: 25932884
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s.
    Kelesidis T; Tran TT; Stein JH; Brown TT; Moser C; Ribaudo HJ; Dube MP; Murphy R; Yang OO; Currier JS; McComsey GA
    Clin Infect Dis; 2015 Aug; 61(4):651-60. PubMed ID: 25904376
    [TBL] [Abstract][Full Text] [Related]  

  • 118. Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257.
    Ofotokun I; Na LH; Landovitz RJ; Ribaudo HJ; McComsey GA; Godfrey C; Aweeka F; Cohn SE; Sagar M; Kuritzkes DR; Brown TT; Patterson KB; Para MF; Leavitt RY; Villasis-Keever A; Baugh BP; Lennox JL; Currier JS;
    Clin Infect Dis; 2015 Jun; 60(12):1842-51. PubMed ID: 25767256
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Renal tubular dysfunction associated with tenofovir therapy.
    Mitra S; Priscilla R; Rajeev K; Sauradeep S; Rajkumar S; Cherian AO
    J Assoc Physicians India; 2014 Jul; 62(7):580-2. PubMed ID: 25672029
    [TBL] [Abstract][Full Text] [Related]  

  • 120. Discontinuation of tenofovir disoproxil fumarate for presumed renal adverse events in treatment-naïve HIV-1 patients: meta-analysis of randomized clinical studies.
    Winston J; Chonchol M; Gallant J; Durr J; Canada RB; Liu H; Martin P; Patel K; Hindman J; Piontkowsky D
    HIV Clin Trials; 2014; 15(6):231-45. PubMed ID: 25433663
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.